The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.
Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.
Raphaëlle Bourdet-Sicard from Danone Nutricia Research discusses a study which investigates the use of a mixed prebiotic formulation to enhance iron absorption while mitigating adverse effects on gut microbiota.
Targeting L-kynurenine metabolism could be a therapeutic strategy for managing Crohn’s disease.
The findings suggest that the composition of the gut microbiota in early life is not a key factor in obesity risk.
New research has now uncovered differences in the gut microbiota composition between people with the condition and those without.
Professor Maria Rescigno explores the critical role of the gut microbiota in maintaining intestinal barrier integrity and its implications for health.
Specific gut microbiota features correlate with better responses to immunotherapy in people with melanoma.
Nathalie Maria Delzenne from Université Catholique de Louvain (Belgium) explains how gut microbiota and systemic inflammation impact cravings and depressive symptoms in affected individuals.
The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.
